TC方案联合放疗对于高危子宫内膜癌术后的疗效及安全性分析

目的：评价TC方案联合放疗作为高危子宫内膜癌术后辅助治疗的临床疗效并分析其安全性。方法整群选取2014年7月-2016年7月期间首次于该院就诊并行规范手术的高危子宫内膜癌患者96例,随机均分两组,每组48例。治疗组TC方案联合放疗,对照组给予放疗,比较2组患者的复发率、转移率、5年生存率等。结果治疗组局部复发率与远处转移率均较对照组低(4.2% vs 18.8%,χ2=5.031,P=0.025),而5年总生存率则高于对照组(6.3% vs 20.8%,χ2=4.360,P=0.037)。治疗组中虽然骨髓抑制反应较对照组发生差异有统计学意义(89.6% vs 70.8%,χ2=5.315,P=0.021),经药物治疗可逐渐恢复。结论 TC方案联合放疗对于术后高危子宫内膜癌患者是较佳的辅助治疗方案,安全可靠。

The Efficacy and Safety of TC Combined with Radiotherapy Regimen in High-risk Endometrial Cancer Treatment

Objective To evaluate the efficacy and safety of TC regimen combined with radiotherapy as adjuvant therapy for high-risk endometrial cancer patients. Methods Group selection the first time received treatment in our hospital, 96 pa-tients with high-risk endometrial cancer were randomly divided into two groups. 48 cases in the treatment group were treat-ed with TC regimen combined with radiotherapy. 48 cases in the control group were treated by radiotherapy alone. The re-currence rate, metastasis rate, 5 year survival rate and drug toxicity of the 2 groups were compared. Results The local re-currence rate and distant metastasis rate in the treatment group were significantly lower than that in the control group(4.2%vs 18.8%,χ2=5.031,P=0.025). While the 5 year overall survival rate was significantly higher than that in the control group (6.3%vs 20.8%,χ2=4.360,P=0.037). Although the bone marrow inhibition reaction in the treatment group was significant-ly higher than that of the control group (89.6% vs 70.8%,χ2=5.315,P=0.021), but the treatment group could be recovered gradually through drug therapy. Conclusion TC regimen combined with radiotherapy for patients with high-risk endometrial cancer is a better adjuvant therapy, safe and reliable.